Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...
GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing outcomes for 177 Lu-PSMA-617 with and without concurrent use of androgen receptor pathway ...
GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Elizabeth Plimack discussing two abstracts: “Adjuvant nivolumab vs placebo for high-risk ...
Data from the first-in-human radioligand-therapy for muscle invasive bladder cancer (MIBC) using Pentixapharm's Lu177-PentixaTher compound will be shown at the American Society of Clinical Oncology's ...
ConferenceFirst-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025 13.02.2025 / 14:10 CET/CESTThe issuer is ...
ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback